Skip to main content


Fig. 4 | BMC Cancer

Fig. 4

From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Fig. 4

A case of metastatic disease to the liver and lungs in which volume indicated progressive disease earlier than RECIST. a PD was identified at 28-week follow-up by volume (+71.4 %), but not until 36-week follow-up by RECIST (+23.9 %). b A 3D rendering of this patient's tumors demonstrates the potential importance of measuring total tumor volume to determine treatment effect

Back to article page